Results 141 to 150 of about 89,766 (303)

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source

Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of AD involves the aggregation of abnormal brain proteins, specifically beta-amyloid plaques and tau ...
Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Kulsoom Babar, Syed Muhammad Sinaan Ali, Abdul Raheem   +5 more
doaj   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission

Small, EarlyView.
Engineered malaria antigens enable in vivo bioconjugation to submicron biopolymer particles in E. coli. Two antigens are co‐tethered at high density and defined stoichiometry. The resulting thermostable particles elicit strong, durable antibody and T‐cell responses, conferring robust protection and blocking mosquito transmission.
Nivethika Sivakumaran, Yevel Flores‐Garcia, Chanel M. Naar, Shuxiong Chen, Mili Mehta, Fijs W. B. van Leeuwen, Abhai Tripathi, Rajagopal Murugan, Meta Roestenberg, Fidel Zavala, Bernd H. A. Rehm   +10 more
wiley   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando, Giuseppe Licci, Marella Reale, Veronica Seccia, Alessia Giorli, Paolo Iannicelli, Dario Zaccari, Valentina Rossi, Jacopo Cambi, Stefano Berrettini, Marco Mandalà, Gianluca Leopardi, Antonio Sarno, Luca Muscatello, Simone Bocuzzi, Franco Trabalzini, Giandomenico Maggiore, Oreste Gallo   +17 more
wiley   +1 more source

Targeting cancer expressed EGFR with a humanized monoclonal antibody. [PDF]

Sci Rep
Costa TGF, Sarnovsky R, Zhan J, Maslanka CA, Obiorah I, Xia D, FitzGerald D, Antignani A.   +7 more
europepmc   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source